Announcement Regarding the Resumption of Shipments for Dry Eye Treatment “DIQUAS LX Ophthalmic Solution 3%”

October 16, 2025, Osaka, Japan – Santen Pharmaceutical Co., Ltd. (hereinafter Santen) announced that shipments of the dry eye treatment “DIQUAS LX Ophthalmic Solution 3%,” currently suspended, are scheduled to resume in early December 2025.

The product was subject to voluntary recall from medical institutions in May 2024 following confirmation of a decrease in preservative concentration identified in certain lots. After determining contributing factors to the decline in preservative concentration and implementing appropriate countermeasures, manufacturing has now resumed. Shipments are expected to begin in early December. Further details will be communicated to healthcare professionals once they have been finalized. This matter will have no impact on the consolidated financial forecast for the fiscal year ending March 2026.

Santen remains committed to ensuring the quality and safety of its pharmaceutical products. Measures have been reinforced to support continued confidence among patients and healthcare professionals.

About Santen
As a specialized company dedicated to eye health, Santen aspires to contribute to the realization of “Happiness with Vision” by providing products and services to patients, consumers, and medical professionals around the world. Since its establishment, and guided by its CORE PRINCIPLE, “Tenki ni sanyo suru,” Santen has been committed to helping people maintain and improve their eye health for more than 130 years. Santen is engaged in the global research and development, manufacturing, and sales and marketing of pharmaceutical products in the field of eye care, supporting the eye health of approximately 50 million people in more than 60 countries and regions worldwide. Santen’s mission is to provide essential and significant value to patients and society in the prevention, diagnosis, and treatment of eye diseases through products and services created from its expertise in the ophthalmology field and from the patient's perspective. To create a future in which as many patients as possible can lead happy and fulfilling lives, Santen is committed to doing its utmost to realize a society in which people around the world can experience “Happiness with Vision.”
For more information, please visit Santen’s website https://www.santen.com/en.

Contact
Corporate Communications
Santen Pharmaceutical Co., Ltd.
E-mail: communication@santen.com